natgillin/translations-raw huggingface dataset:
Samtidig administration af højere doser af enten efavirenz eller carbamazepin er ikke undersøgt.
Co- administration of higher doses of either efavirenz or carbamazepine has not been studied.
Samtidig administration af IKERVIS med øjendråber, der indeholder kortikosteroider, kan forstærke IKERVIS' virkninger på immunsystemet (se pkt.
Co-administration of IKERVIS with eye drops containing corticosteroids could potentiate the effects of IKERVIS on the immune system (see section 4.5).
Samtidig administration af INCIVO og quetiapin er kontraindiceret, da quetiapin- relateret toksicitet derved kan øges.
Concomitant administration of INCIVO and quetiapine is contraindicated as it may increase quetiapine-related toxicity.
Samtidig administration af induktorer af metaboliske enzymer
Co-administration with inducers of metabolic enzymes
Samtidig administration af INVEGA 12 mg en gang dagligt og divalproexnatrium-depottabletter (500 mg til 2.000 mg en gang dagligt) påvirkede ikke steady-state-farmakokinetikken for valproat.
Co-administration of INVEGA 12 mg once daily with divalproex sodium prolonged-release tablets (500 mg to 2000 mg once daily) did not affect the steady-state pharmacokinetics of valproate.
Samtidig administration af Ipreziv 40 og 80 mg med en kalciumkanalblokker (amlodipin) eller et diuretikum af thiazid-typen (chlortalidon) resulterede i yderligere blodtryksreduktion sammenlignet med de andre antihypertensiva alene.
Coadministration of Ipreziv 40 and 80 mg with a calcium channel blocker (amlodipine) or a thiazide- type diuretic (chlortalidone) resulted in additional blood pressure reductions compared with the other antihypertensive alone.
Samtidig administration af ISENTRESS og andre lægemidler, der øger pH i mavesækken (f.eks. omeprazol og famotidin), kan øge absorptionen af raltegravir og resultere i øget plasmakoncentration af raltegravir (se tabel 1).
Co-administration of ISENTRESS with other agents that increase gastric pH (e.g., omeprazole and famotidine) may increase the rate of raltegravir absorption and result in increased plasma levels of raltegravir (see Table 1).
Samtidig administration af ISENTRESS og andre lægemidler, der øger pH i mavesækken (f.eks. omeprazol og famotidin), kan øge absorptionen af raltegravir og resultere i øget plasmakoncentration af raltegravir (se tabel 2).
Co-administration of ISENTRESS with other agents that increase gastric pH (e.g., omeprazole and famotidine) may increase the rate of raltegravir absorption and result in increased plasma levels of raltegravir (see Table 2).
Samtidig administration af ISENTRESS og andre lægemidler, der øger pH i mavesækken (f.eks. omeprazol og famotidin), kan øge absorptionen af raltegravir og resultere i øget plasmakoncentration af raltegravir (se tabel 3).
Co-administration of ISENTRESS with other agents that increase gastric pH (e.g., omeprazole and famotidine) may increase the rate of raltegravir absorption and result in increased plasma levels of raltegravir (see Table 3).
Samtidig administration af ISENTRESS og antacida, der indeholder divalente metalkationer, kan reducere absorptionen af raltegravir på grund af kelation, hvilket medfører et fald i raltegravirs plasmakoncentration.
Co-administration of ISENTRESS with antacids containing divalent metal cations may reduce raltegravir absorption by chelation, resulting in a decrease of raltegravir plasma levels.
Samtidig administration af ISENTRESS og antacida, der indeholder divalente metalkationer, kan reducere absorptionen af raltegravir på grund af kelation, hvilket medfører et fald i raltegravirs plasmakoncetration.
Co-administration of ISENTRESS with antacids containing divalent metal cations may reduce raltegravir absorption by chelation, resulting in a decrease of raltegravir plasma levels.
Samtidig administration af ISENTRESS og et calciumcarbonatholdigt antacidum reducerede raltegravirs plasmakoncentration; denne interaktion anses dog ikke for klinisk relevant.
Co-administration of ISENTRESS with a calcium carbonate antacid decreased raltegravir plasma levels; however, this interaction is not considered clinically meaningful.
Samtidig administration af Kaletra med rifampicin anbefales ikke, da faldet i lopinavir- koncentrationen igen kan nedsætte den terapeutiske effekt af lopinavir betydeligt.
Co-administration of Kaletra with rifampicin is not recommended as the decrease in lopinavir concentrations may in turn significantly decrease the lopinavir therapeutic effect.
samtidig administration af Kaletra og
administering Kaletra with
Samtidig administration af Kaletra og
Concomitant administration of
Samtidig administration af Kaletra og boceprevir anbefales ikke.
It is not recommended to
Samtidig administration af Kaletra og quetiapin er kontra-indiceret (se pkt.
Therefore, concomitant administration of Kaletra with salmeterol is not recommended (see section 4.4).
Samtidig administration af Kaletra og rilpivirin øger rilpivirin-plasma- koncentrationen, men dosisjustering er ikke nødvendig.
Concomitant use of Kaletra with rilpivirine causes an increase in the plasma concentrations of rilpivirine, but no dose adjustment is required.
Samtidig administration af Kaletra og simeprevir anbefales ikke
co-administer Kaletra and
Samtidig administration af Kaletra og simeprevir anbefales ikke.
The dose of Kaletra may need adjusting.
Samtidig administration af Kaletra og tadalafil
co-administer Kaletra and
Samtidig administration af Kaletra og tadalafil anbefales ikke.
of Kaletra with tadalafil is not recommended.
Samtidig administration af Ketek og colchicin er kontraindiceret hos patienter med nedsat nyre- og / eller leverfunktion (se pkt 4,3).
Concomitant administration of Ketek and colchicine is contraindicated in patients with renal and/or hepatic impairment (see section 4.3).
Samtidig administration af ketoconazol (400 mg oralt en gang dagligt) og salmeterol (50 mikrogram inhaleret to gange dagligt) i 7 dage hos 15 raske personer medførte signifikant øget plasma-eksponering af salmeterol (1,4 gange Cmax og 15 gange AUC).
Co-administration of ketoconazole (400 mg orally once daily) and salmeterol (50 micrograms inhaled twice daily) in 15 healthy subjects for 7 days resulted in a significant increase in plasma salmeterol exposure (1.4- fold Cmax and 15-fold AUC).
Samtidig administration af kraftige CYP3A4-hæmmere (f.eks. boceprevir, clarithromycin, cobicistat, indinavir, itraconazol, ketoconazol, nefazodon, nelfinavir, posaconazol, ritonavir, saquinavir, telaprevir, telithromycin, voriconazol) og kraftige CYP3A4-induktorer (f.eks. carbamazepin, phenobarbital, phenytoin, rifampicin, prikbladet perikon (Hypericum perforatum)) (se pkt.
Concomitant administration of strong CYP3A4 inhibitors (e.g. boceprevir, clarithromycin, cobicistat, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole) and strong CYP3A4 inducers (e.g. carbamazepine, phenobarbital, phenytoin, rifampicin, St John’s wort (Hypericum perforatum) (see section 4.5).
Samtidig administration af kraftige eller moderate CYP3A4-hæmmere (proteasehæmmere, svampemidler af azoltypen, makrolider som f.eks. erythromycin og clarithromycin samt verapamil og diltiazem) kan give anledning til signifikant stigning i amlodipins plasmakoncentration.
Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure.
Samtidig administration af lamivudin og høje doser af trimethoprim/sulfamethoxazol til behandling af Pneumocystis carinii pneumoni (PCP) og toxoplasmose bør undgås.
Co-administration of lamivudine with high doses of co-trimoxazole for the treatment of Pneumocystis carinii pneumonia (PCP) and toxoplasmosis should be avoided.
Samtidig administration af lamivudin og høje doser af trimethoprim/sulfamethoxazol til behandling af Pneumocystis carinii-pneumoni (PCP) og toxoplasmose bør undgås.
Co-administration of lamivudine with high doses of co-trimoxazole for the treatment of Pneumocystis carinii pneumonia (PCP) and toxoplasmosis should be avoided.
Samtidig administration af lamivudin og OCT- og MATE-hæmmere kan muligvis øge eksponeringen for lamivudin.
Co-administration of lamivudine with OCT and MATE inhibitors could increase lamivudine exposure.
Samtidig administration af lenalidomid 10 mg/dag øgede digoxins plasmaeksponering (0,5 mg, enkeltdosis) med 14 % med 90 % CI (konfidensinterval) [0,52 %-28,2 %].
Concomitant administration with lenalidomide 10 mg/day increased the plasma exposure of digoxin (0.5 mg, single dose) by 14% with a 90% CI (confidence interval) [0.52%-28.2%].
Samtidig administration af lenalidomid ændrer ikke temsirolimus’ farmakokinetik.
Co-administration of lenalidomide does not alter the pharmacokinetics of temsirolimus.
Samtidig administration af levende vacciner og Inflectra frarådes.
The concurrent adminstration of live vaccines with Inflectra is not recommended.
Samtidig administration af levende vacciner og Remsima frarådes.
The concurrent administration of live vaccines with Remsima is not recommended.
Samtidig administration af Levodopa/Carbidopa/Entacapone Orion og non-selektive monoaminooxidase (MAO-A og MAO-B)-hæmmere (f.eks. phenelzin, tranylcypromin).
Coadministration of Levodopa/Carbidopa/Entacapone Orion with non-selective monoamine oxidase (MAO-A and MAO-B) inhibitors (e.g. phenelzine, tranylcypromine).
Samtidig administration af lithium og Actelsar HCT kan ikke anbefales.
Co-administration of lithium and Actelsar HCT is not recommended.
Samtidig administration af lithium og MicardisPlus kan ikke anbefales (se pkt.
Co- administration of lithium and MicardisPlus is not recommended (see section 4.4).
Samtidig administration af lopinavir/ritonavir med rifampicin anbefales ikke, da faldet i lopinavir-koncentrationen igen kan nedsætte den terapeutiske effekt af lopinavir betydeligt.
Co-administration of lopinavir/ritonavir with rifampicin is not recommended as the decrease in lopinavir concentrations may in turn significantly decrease the lopinavir therapeutic effect.
Samtidig administration af lurasidon og digoxin (et P-gp-substrat) forøgede ikke eksponeringen over for digoxin og forøgede kun i let grad Cmax (1,3 gange), og i denne sammenhæng betragtes det som sikkert at administrere lurasidon sammen med digoxin.
Coadministration of lurasidone with digoxin (a P-gp substrate) did not increase the exposure to digoxin and only slightly increased Cmax (1.3 –fold) and therefore, it is considered that lurasidone can be coadministered with digoxin.
Samtidig administration af lægemidler, der er CYP3A-substrater og har et snævert terapeutisk indeks og med hvilke forhøjede plasmakoncentrationer associeres med alvorlige og/eller livstruende bivirkninger, er kontraindiceret sammen med EVOTAZ.
Co-administration of medicinal products that are substrates of CYP3A and have narrow therapeutic indeces and for which elevated plasma concentrations are associated with serious and/or life- threatening events are contraindicated with EVOTAZ.
Samtidig administration af lægemidler, der inducerer CYP3A4-aktivitet, kan reducere effekten af Instanyl.
Co-administration with medicinal products that induce 3A4 activity may reduce the efficacy of Instanyl.
Samtidig administration af lægemidler, der øger gastrisk pH
Coadministration with medicinal products that increase gastric pH
Samtidig administration af lægemidler, som hæmmer optagelsestransportøren (rifampicin, ciclosporin) eller effluxtransportøren (ritonavir) kan øge den systemiske eksponering for  valsartan.
Co-administration of inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir) may increase the systemic exposure  to valsartan.
Samtidig administration af lægemidler, som hæmmer optagelsestransportøren (rifampicin, ciclosporin) eller effluxtransportøren (ritonavir) kan øge den systemiske eksponering for valsartan.
Co-administration of inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir) may increase the systemic exposure  to valsartan.
Samtidig administration af medicin, der er kendt for at forlænge QT-intervallet.
Concomitant medicinal product that is known to prolong QTc interval.
Samtidig administration af medicin, der er kendt for at forlænge QTc-intervallet.
Concomitant medicinal product that is known to prolong QTc interval.
Samtidig administration af memantin og antispasmotika, dantrolen eller baclofen kan modificere disses virkninger, og dosisjustering kan være nødvendig.
Concomitant administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify their effects and a dose adjustment may be necessary.
Samtidig administration af midazolam og nelfinavir kan forårsage en stor stigning i koncentrationen af dette benzodiazepin.
Co- administration of midazolam with nelfinavir may cause a large increase in the concentration of this benzodiazepine.
Samtidig administration af moderate (f.eks. erythromycin, grapefrugtjuice, verapamil) eller potente (f.eks. ketoconazol, ritonavir, nefazodon, itraconazol, telithromycin, clarithromycin) CYP3A4- hæmmere og ulipristalacetat anbefales ikke (se pkt.
Co-administration of moderate (e.g. erythromycin, grapefruit juice, verapamil) or potent (e.g. ketoconazole, ritonavir, nefazodone, itraconazole, telithromycin, clarithromycin) CYP3A4 inhibitors and ulipristal acetate is not recommended (see section 4.5).
Samtidig administration af naloxegol og quinidin antagoniserede ikke den morfininducerede miosis-effekt, hvilket tyder på, at P-gp- hæmning ikke har nogen betydelig indvirkning på naloxegols evne til at krydse blod-hjernebarrieren i terapeutiske doser.
Co-administration of naloxegol and quinidine did not antagonize the morphine-induced miosis effect, suggesting that P-gp inhibition does not meaningfully change the capacity of naloxegol to cross the blood-brain barrier at therapeutic doses.
Samtidig administration af nelarabin og adenosindeaminasehæmmere, så som pentostatin frarådes.
Concomitant administration of nelarabine in combination with adenosine deaminase inhibitors, such as pentostatin is not recommended.
Samtidig administration af nelfinavir og omeprazol kan forårsage tab af virologisk respons og derfor er samtidig brug kontraindiceret.
virologic response and therefore concomitant use is contra- indicated.
Samtidig administration af nevirapin og elvitegravir forventes at reducere plasmakoncentrationen af elvitegravir, hvilket kan forårsage svigtende terapeutisk virkning og mulig udvikling af resistens.
Co-administration of nevirapine and elvitegravir is expected to decrease elvitegravir plasma concentrations which may result in loss of therapeutic effect and possible development of resistance.
Samtidig administration af NSAID’er anbefales ikke til patienter med nedsat nyrefunktion.
In patients with impaired renal function, concomitant administration of NSAIDs is not recommended.
Samtidig administration af Odefsey og andre lægemidler, som hæmmer P-gp (f.eks. ketoconazol, fluconazol, itraconazol, posaconazol, voriconazol, ciclosporin), forventes at øge absorptionen og plasmakoncentrationen af tenofoviralafenamid.
Co-administration of Odefsey with other medicinal products that inhibit P-gp (e.g. ketoconazole, fluconazole, itraconazole, posaconazole, voriconazole, ciclosporin) is expected to increase the absorption and plasma concentration of tenofovir alafenamide.
Samtidig administration af olaparib og potente CYP3A-induktorer frarådes (se pkt.
Olaparib co-administration with strong CYP3A inducers is not recommended (see section 4.5).
Samtidig administration af olaparib og potente eller moderate CYP3A-inhibitorer frarådes (se pkt.
Olaparib co-administration with strong or moderate CYP3A inhibitors is not recommended (see section 4.5).
Samtidig administration af OLYSIO og ciclosporin anbefales ikke, da dette giver signifikant højere eksponering for simeprevir baseret på foreløbige data fra et igangværende fase 2-studie med HCV- inficerede levertransplanterede patienter (se pkt.
Co-administration of OLYSIO with ciclosporin is not recommended as this leads to significantly higher exposure of simeprevir based on interim data from an ongoing phase 2 study in HCV infected post-liver transplant patients (see section 4.5).
Samtidig administration af omeprazol (40 mg qd) reducerede gennemsnitlig nelfinavir AUC, Cmax og Cmin med 36-39 %, og gennemsnitlig AUC, Cmax og Cmin for den farmakologisk aktive metabolit M8 blev reduceret med 75-92 %.
Co-administration of omeprazole (40 mg qd) reduced mean nelfinavir AUC, Cmax and Cmin by 36–39 % and mean AUC, Cmax and Cmin for the pharmacologically active metabolite M8 was reduced by 75-92%.
Samtidig administration af ONIVYDE og 5-FU/LV ændrer ikke de farmakokinetiske egenskaber for ONIVYDE baseret på en populationsfarmakokinetisk analyse.
Co-administration of ONIVYDE+5-FU/LV does not alter the pharmacokinetics of ONIVYDE based on the population pharmacokinetic analysis.
Samtidig administration af oral voriconazol og oral fluconazol hos frivillige, raske forsøgspersoner resulterede i en signifikant stigning i Cmax og AUCτ for voriconazol.
Coadministration of oral voriconazole and oral fluconazole resulted in a significant increase in Cmax and AUCτ of voriconazole in healthy subjects.
Samtidig administration af oralt inhaleret indacaterol og glycopyrronium ved steady-state for begge komponenter påvirkede ikke farmakokinetikken for nogen af komponenterne.
Concomitant administration of orally inhaled indacaterol and glycopyrronium, under steady-state conditions of both components, did not affect the pharmacokinetics of either component.
Samtidig administration af P- glykoproteinhæmmere, f.eks. ciclosporin og verapamil kan medføre ændret distribution og/eller ændret elimination af erlotinib.
Concomitant administration of inhibitors of Pgp, e.g. cyclosporine and verapamil, may lead to altered distribution and/or altered elimination of erlotinib.
Samtidig administration af P- glykoptoteinhæmmere, f.eks. ciclosporin og verapamil kan medføre ændret distribution og/eller ændret elimination af erlotinib.
Concomitant administration of inhibitors of Pgp, e.g. cyclosporine and verapamil, may lead to altered distribution and/or altered elimination of erlotinib.
Samtidig administration af P-gp- inhibitorer (såsom amiodaron, verapamil, kinidin, ketoconazol, dronedaron, clarithromycin og ticagrelor) forventes at resultere i en øget dabigatran plasmakoncentration.
Concomitant administration of P-gp inhibitors (such as amiodarone, verapamil, quinidine, ketoconazole, dronedarone, clarithromycin and ticagrelor) is expected to result in increased dabigatran plasma concentrations.
Samtidig administration af P-gp-inhibitorer (hvoraf nogle er kontraindiceret, se pkt.
P-gp inhibitor co-medication (some P-gp inhibitors are contraindicated, see section
Samtidig administration af Pandemisk influenzavaccine H5N1 MedImmune og inaktiverede vacciner eller den sæsonbetingede influenzavaccine Fluenz Tetra er ikke undersøgt.
The co-administration of Pandemic influenza vaccine H5N1 MedImmune with inactivated vaccines or with the seasonal vaccine Fluenz Tetra has not been studied.
Samtidig administration af para-aminosalicylsyre og ethionamid kan forstærke bivirkningerne af para- aminosalicylsyre, hovedsagelig de gastrointestinale virkninger, herunder ikterus, hepatitis, kvalme, opkastning, diarré, abdominalsmerter eller anoreksi.
Co-administration of para- aminosalicylic acid and ethionamide may intensify adverse reactions of para-aminosalicylic acid, mainly the gastrointestinal effects, including jaundice, hepatitis, nausea, vomiting, diarrhoea, abdominal pain or anorexia.
Samtidig administration af parecoxib 40 mg i.v. og propofol (CYP2C9-substrat) eller midazolam (CYP3A4-substrat) påvirker hverken farmakokinetikken (metabolisme og eksponering) eller farmakodynamikken (EEG-påvirkninger, psykomotoriske tests og opvågning fra sedation) for propofol i.v. eller midazolam i.v.
Coadministration of IV parecoxib 40 mg with propofol (CYP2C9 substrate) or midazolam (CYP3A4 substrate) did not affect either the pharmacokinetics (metabolism and exposure) or the pharmacodynamics (EEG effects, psychomotor tests and waking from sedation) of IV propofol or IV midazolam.
Samtidig administration af parecoxib og heparin påvirkede ikke heparins farmakodynamik (aktiveret partiel thromboplastintid) sammenlignet med heparin administreret alene.
Co-administration of parecoxib and heparin did not affect the pharmacodynamics of heparin (activated partial thromboplastin time) compared to heparin alone.
Samtidig administration af pazopanib (400 mg én gang daglig) og den kraftige CYP3A4- og P-gp- hæmmer ketoconazol (400 mg én gang daglig) i 5 på hinanden følgende dage resulterede i en stigning på 66 % og 45 % i middelværdierne af henholdsvis AUC(0-24) og Cmax for pazopanib i forhold til administration af pazopanib alene (400 mg én gang daglig i 7 dage).
Concurrent administration of pazopanib (400 mg once daily) with the strong CYP3A4 and P-gp inhibitor, ketoconazole (400 mg once daily) for 5 consecutive days, resulted in a 66 % and 45 % increase in mean pazopanib AUC(0-24) and Cmax, respectively, relative to administration of pazopanib alone (400 mg once daily for 7 days).
Samtidig administration af pazopanib og andre kraftige hæmmere af CYP3A4-familien (f.eks. itraconazol, clarithromycin, atazanavir, indinavir, nefazodon, nelfinavir, ritonavir, saquinavir, telithromycin og voriconazol) kan øge koncentrationen af pazopanib.
Co-administration of pazopanib with other strong inhibitors of the CYP3A4 family (e.g., itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) may increase pazopanib concentrations.
Samtidig administration af PDE 5-hæmmere (såsom sildenafil, tadalafil, vardenafil) (se pkt.
Co-administration with PDE 5 inhibitors (such as sildenafil, tadalafil, vardenafil) (see section 4.5).
Samtidig administration af peginterferon alfa-2b (ViraferonPeg) og caffein eller desipramin øger i beskeden grad eksponeringen for koffein og desipramin.
Concomitant administration of peginterferon alfa-2b (ViraferonPeg) with caffeine or desipramine modestly increased the exposure of caffeine and desipramine.
Samtidig administration af perikon (se pkt.
Coadministration with St John’s Wort (see section 4.5).
Samtidig administration af perikon (se pkt.
Coadministration with St. John’s Wort (see section 4.5).
Samtidig administration af posaconazol og CYP3A4- substrater kan resultere i en stor stigning i eksponering for CYP3A4-substrater som eksemplificeret nedenfor ved virkningen på tacrolimus, sirolimus, atazanavir og midazolam.
Co-administration of posaconazole with CYP3A4 substrates may result in large increases in exposure to CYP3A4 substrates as exemplified by the effects on tacrolimus, sirolimus, atazanavir and midazolam below.
Samtidig administration af posaconazol og rifabutin bør undgås, medmindre fordelen for patienten opvejer risikoen (se også ovenfor vedrørende indvirkningen af rifabutin på plasmaniveauer af posaconazol).
Concomitant use of posaconazole and rifabutin should be avoided unless the benefit to the patient outweighs the risk (see also above regarding the effect of rifabutin on plasma levels of posaconazole).
Samtidig administration af posaconazol og sirolimus anbefales ikke og bør undgås, når det er muligt.
Co- administration of posaconazole with sirolimus is not recommended and should be avoided whenever possible.
Samtidig administration af posaconazol og terfenadin, astemizol, cisaprid, pimozid, halofantrin eller quinidin er kontraindiceret.
Co-administration of posaconazole and terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine is contraindicated.
Samtidig administration af posaconazol og vinkaalkaloider bør derfor undgås, medmindre fordelen for patienten opvejer risikoen.
Therefore, concomitant use of posaconazole and vinca alkaloids should be avoided unless the benefit to the patient outweighs the risk.